Peptide Ads That Stay Approved
We help peptide and GLP-1 brands run compliant Meta and Google ads that survive medical-policy review, stay live through scale, and end the cycle of rejected campaigns and disabled accounts.
Overview
Approved Peptide and GLP-1 Ads
Peptide brands rarely have a market problem. GLP-1, recovery, and longevity products are in the middle of a demand boom — the real constraint is that ad platforms classify peptides as unapproved medical products and shut campaigns down before they ever prove out.
Meta and Google do not read a peptide ad the way they read a supplement ad. A single compound name, dosage line, or “research use only” disclaimer can route an entire account into medical-policy review, where the default answer is no.
Approved Ads works only with restricted and regulated brands, and peptides sit at the sharpest end of that: part wellness, part pharmaceutical, wholly platform-sensitive. We build ad setups that keep peptide and GLP-1 campaigns inside policy so they get approved, stay live, and scale.
The result is a peptide advertising program built on approval stability — not a monthly reset of banned ad accounts, rejected creatives, and appeals that lead nowhere.
The ceiling on peptide advertising is not demand — it is classification. The moment a platform reads a product as a peptide, it stops evaluating performance and starts evaluating medical and safety risk.
That risk assessment is broad. Google’s Speculative and Experimental Medical Treatments policy and Meta’s rules on unsafe substances and personal-health claims mean compound names (semaglutide, tirzepatide, BPC-157, TB-500), dosing language, injectable formats, before-and-after framing, and even “research use only” labeling can each trip enforcement on their own.
Most peptide brands arrive with a supplement or DTC ecommerce build — exactly the pattern platforms are trained to flag in a pharmaceutical-adjacent category. Product pages, ingredient collections, and health claims are scanned together, and the account inherits risk from all of it.
Then it compounds. A rejected GLP-1 ad tightens review on the next one; a disabled account follows the business manager to the one after that. Left alone, the setup is classified as high-risk until even cautious, compliant peptide ads stop clearing.
How We Get Peptide Ads Approved
Peptides need a different playbook than any unrestricted category, because approval — not creative or bidding — is the real bottleneck. Our work starts at the account and policy layer, not the campaign layer, as part of our wider restricted ads agency approach.
We begin by mapping how Meta and Google will read the specific brand: which compounds are named, whether products are positioned as research, cosmetic, or wellness, how claims are worded, how injectables and dosages appear, and what the site’s history and structure signal. That shows where enforcement will land before a single ad is submitted.
From there we build a peptide-specific ad structure. Risk is compartmentalized across account setup, traffic routing, and platform-safe landing pages, so no single rejection takes down the whole program and platforms scan less of the ecosystem at once.
Creative and copy are written to peptide policy, not supplement instinct. We know which words, claims, and visuals push a GLP-1 or research-peptide ad into medical review — and how to communicate benefit and brand without making the claims that trigger it.
Landing pages are treated as part of the ad, because platforms treat them that way. Pages are structured to satisfy medical-policy review, keep claims defensible, and still convert, with disclaimers, eligibility, and framing handled deliberately rather than bolted on.
Once live, we scale against approval health rather than ambition, pacing budgets to review behavior and account signals across Meta and Google. The outcome is a peptide advertising system that stays live long enough to compound, instead of resetting every time a platform re-reads the category.
No single channel carries a peptide brand, and none can be run the way an unrestricted store runs it. Meta, Google, email, and TikTok each read peptides differently, but all of them judge the whole setup, not the individual ad.
We run peptide advertising as one coordinated system. Search captures the high-intent demand around GLP-1 and recovery, paid social builds the audience, and email owns the margin — each configured to send the same low-risk signals so one channel does not flag another.
Because peptides straddle wellness and pharmaceutical regulation, every channel is adapted to that reality. Google Search leans on controlled, compliant terms and pages while Shopping and broad medical claims stay off the table; Meta relies on platform-safe creative and landing pages rather than direct compound promotion.
Email and SMS carry weight here that they do not in easier niches. Because paid reach is capped and volatile, retention and repeat purchase through Klaviyo are often where a peptide brand actually makes its money — and they are never exposed to ad-platform review.
Coordinated instead of siloed, the channels spread risk instead of stacking it. That is what lets a peptide program grow without the repeated shutdowns and forced account resets that end most attempts.
Peptide Ads cases
Explorer all cases
Why do peptide ads keep getting rejected on Meta and Google?
Peptide ads are usually rejected on risk signals, not the product itself. The common triggers are:
- Health, dosage or treatment claims in the ad or on the landing page
- “Research use only” or “not for human consumption” language
- Compound names such as semaglutide, BPC-157 or TB-500
- Before-and-after or body-transformation imagery
- A high rejection rate that pushes the whole account toward a ban
Platforms review the ad, landing page and account history together, so a clean ad can still fail on the setup around it.
Can you advertise peptides on Google Ads?
Yes, but only under Google’s Healthcare and Medicines and Speculative and Experimental Medical Treatments policies. In practice that means:
- Search as the main entry point, rarely Shopping
- Compliant, non-medical wording and controlled landing pages
- No unapproved-drug, dosage or treatment claims
Approval hinges on how the brand and its pages are structured, not on budget.
Can you run Meta (Facebook and Instagram) ads for a peptide brand without getting banned?
Yes, when risk is controlled. Meta reads peptides under its Unsafe Substances and Personal Health Attributes standards, so a stable setup needs:
- Platform-safe creative with no direct compound or before/after claims
- No “negative self-perception” or body-shaming angles
- Landing pages built to survive review
- A verified Business Manager with clean history
Meta weighs the ad, page and account together — stability comes from the whole setup, not one ad.
Can you advertise GLP-1 products like semaglutide or tirzepatide?
GLP-1 advertising is possible but sits under the strictest rules on both platforms — Meta’s Cosmetic Procedures and Weight Loss policy and Google’s prescription-drug rules. It typically requires:
- Careful, claim-free positioning
- Geo- and eligibility-gating
- Compliant landing pages and no before/after weight-loss imagery
Direct promotion of prescription compounds is the fastest route to a ban; a policy-first setup is what keeps GLP-1 campaigns live.
Can you advertise research peptides such as BPC-157 or TB-500?
These are the hardest sub-category, because they are unapproved and sold as “research use only, not for human consumption.” They cannot be promoted like consumer products, but the brand can still be advertised with:
- Controlled, non-medical messaging
- Compliant, defensible landing pages
- Limited account exposure
Viability depends heavily on market, positioning and how the catalog is presented.
Do peptide landing pages get ads banned?
Yes — often more than the ad itself. Google and Meta crawl the landing page, so bans frequently start there. Pages get flagged for:
- Medical, dosage or cure claims
- Missing disclaimers or eligibility information
- How compounds and “research use only” labels are presented
A page built only for conversion, with no policy in mind, is one of the most common reasons otherwise-compliant peptide ads fail.
What words and claims get peptide ads flagged?
Language that frames a peptide as a drug or treatment. The usual flags are:
- Dosage, mg, injection and protocol terms
- Condition or outcome claims (fat loss, healing, muscle, anti-aging)
- Purity or grade claims like “99% pure”
- “Research use only” placed next to consumer-style calls to action
Compliant copy communicates the brand and benefit without making the medical claim that triggers review.
How do you recover a banned or suspended peptide ad account?
Recovery starts with reading the exact policy that was violated, not just re-appealing. The path is usually:
- Identify the triggering signal (ad, landing page or account history)
- Fix the setup before appealing
- Appeal through Business Manager support
- Rebuild on a verified account with clean history
Repeated blind appeals make things worse — each one raises scrutiny.
Is it legal to sell peptides online, and does "research use only" protect you?
A “research use only” or “not for human consumption” label does not exempt a brand from advertising review, and platforms and the FTC increasingly treat marketing as evidence of intended use. For advertising that means:
- Disclaimers do not override how ads and pages are read
- Human-use or treatment claims raise both platform and regulatory risk
- Compliance is about how you advertise, not just how you label
We build campaigns inside platform and FTC advertising rules — we do not help make unapproved-drug claims.
What is the biggest mistake peptide brands make with paid ads?
Running a supplement or ecommerce playbook in a pharmaceutical-adjacent category. The tactics that work for unrestricted products backfire:
- Bold ingredient- and claim-led ads
- Aggressive scaling that spikes the rejection rate
- Blind re-appeals after every rejection
Those are exactly the signals that get accounts flagged, then disabled, then permanently high-risk.
How important are email and SMS for peptide brands?
Critical, because paid reach is capped and can disappear overnight. Owned channels are not subject to ad-platform review, so email and SMS through Klaviyo are often where a peptide brand makes real margin — through retention, repeat purchase and win-back — while paid acquisition stays volatile.
How much does a peptide or GLP-1 marketing agency cost?
Pricing usually works as a monthly management retainer, often with a performance or ad-spend component on top, separate from the media budget you pay the platforms. For peptide brands the real value is not the fee — it is account stability: ads that keep running beat cheap ads that get banned.
How long does it take to get peptide ads approved?
It depends on the starting point. A brand with existing flags or a risky setup usually needs restructuring first; a clean, policy-first build can start clearing quickly. The goal is not a single approval — it is a setup that keeps approving and stays live as you scale.
Your Brand’s Recovery Starts Here
Book an AA meeting today.
Reach out today and discover how we can take your
platform-restricted brand to the next level.